Sean Alan Reade joins Pharm-Olam as Vice President of Global Regulatory Affairs
July 09, 2007 (PRLEAP.COM) Health NewsHOUSTON, TEXAS July 9, 2007. Pharm-Olam International Ltd. (POI), a multi-national, full service CRO to pharmaceutical and biotech industries announces the addition of Sean Alan F. X. Reade as Vice President of Global Regulatory Affairs.
Sean Alan has over 25 years of experience in the pharmaceutical industry, most recently as Director of Regulatory Affairs for PPD, Inc. and as Vice President of Regulatory Affairs at UCB/Celltech. Sean Alan has worked for Maxim Pharmaceuticals, Aronex Pharmaceuticals, Boehringer Ingelheim, and SmithKline.
In his career, Sean Alan has directed the approval of 19 NDAs, 40 clinical SNDAs, and 7 MAAs for branded drug products across multiple therapeutic areas for both start-ups and global pharma. Sean Alan also filed the first full eCTD ever accepted by the EMEA.
Sean Alan holds a MA in Pharmacology from Boston University School of Medicine and received advanced graduate training in pharmacokinetics at the Philadelphia College of Pharmacy and Science.
For further information about conducting trials with Pharm-Olam please contact Iain Gordon, Vice President of Business Development at email@example.com .
About Pharm-Olam International
Pharm-Olam International is a multi-national contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From pre-clinical to Phase IV, POI focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines.